Literature DB >> 7249763

Transient pulmonary hypertension from the intravenous injection of crushed, suspended pentazocine tablets.

H W Farber, R Falls, F L Glauser.   

Abstract

We describe a patient with biopsy-proven pulmonary talc granulomas (secondary to the long-term intravenous injection of crushed tablets of pentazocine) who had two episodes of transient pulmonary hypertension following the injection of this oral medication. We established a canine model and measured the right lymph duct flow, mean pulmonary arterial pressures, and pulmonary vascular resistance to determine the short-term effects on hemodynamics and the flow of lymph after intravenous administration of crushed pentazocine tablets (3 to 4 mg/kg of body weight) or pure talc (2.5 to 3 mg/kg). A typical response to both agents consisted of short-term elevations of mean pulmonary arterial pressure and pulmonary vascular resistance to approximately twice baseline values, with a slow decrement over 30 to 45 minutes. The average flow of lymph tripled, peaking at approximately two hours after injection. The lymph contained high levels of albumin. We concluded that the talc filler in oral tablets of pentazocine induces the pulmonary hypertension, probably by mechanical obstruction of the pulmonary vasculature. Association with this transient pulmonary hypertension is an increase in the permeability of the pulmonary microvasculature.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7249763     DOI: 10.1378/chest.80.2.178

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Crushed it: Elucidation of systemic vasculitis caused by injected hydromorphone tablets via skin biopsy.

Authors:  Robin Rolader; Brian Bishop; Zachary W Eyre; Justin T Cheeley
Journal:  JAAD Case Rep       Date:  2019-10-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.